An investigation on behalf of investors in Puma Biotechnology Inc (NYSE:PBYI) shares over potential wrongdoing at Puma Biotechnology Inc was announced and NYSE:PBYI stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/18/2017 -- An investigation was announced for current long-term investors in shares of Puma Biotechnology Inc (NYSE:PBYI), who have losses from their investment in NYSE:PBYI shares. The investigation concerns potential breaches of fiduciary duties by certain officers and directors at Puma Biotechnology.
Investors who purchased shares of Puma Biotechnology Inc (NYSE:PBYI) have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Puma Biotechnology officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On November 14, 2016, news of an investigation of an open-label Phase 2 clinical trial ("CONTROL") was revealed. The investigation concerned the incidence rate of severe diarrhea (grade 3) in early stage HER2+ breast cancer patients receiving Puma Biotechnology's Neratinib drug (the "incidence rate").
Following this high incidence of approximately 40%, the CONTROL study reportedly investigated the incidence rate where the antidiarrheal prophylaxis Loperamide was dispensed.
The investigation reportedly showed a high incidence rate stayed at about 27% and that the CONTROL study was then extended to include a group of patients who were administered Loperamide and the corticosteroid Budesonide. The incidence rate reportedly did drop, but was still at 12.9%. Shares of Puma Biotechnology (NYSE:PBYI) declined on November 14, 2016 to as low as $32.72 per share.
Those who purchased shares of Puma Biotechnology Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego